Enhancing recovery after stroke with noradrenergic pharmacotherapy: A new frontier?

Canadian Journal of Neurological Sciences

Volumn 27, Issue 2, 2000, Pages 97-105

  Gladstone, David J ^a,b   Black, Sandra E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; ALPHA ADRENERGIC RECEPTOR; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APOMORPHINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CLONIDINE; DESIPRAMINE; DOPAMINE; FIBRINOLYTIC AGENT; FLUOXETINE; HALOPERIDOL; IDAZOXAN; LEVODOPA; METHYLPHENIDATE; NORADRENALIN; PHENOBARBITAL; PHENTERMINE; PHENYLPROPANOLAMINE; PHENYTOIN; PRAZOSIN; SEROTONIN; YOHIMBINE;

APHASIA; BRAIN INJURY; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; INSOMNIA; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; SPEECH THERAPY; STROKE;

EID: 0034084071     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100052173     Document Type: Review

References (109)

1. Hill MD, Hachinski V. Stroke treatment: time is brain. Lancet 1998;352:10-14.
2. Hachinski V. Relevance of rodent models of stroke. Arch Neurol 1996;53:1070.
3. Stroke Unit Trialists. Organised inpatient (stroke unit) care for stroke. The Cochrane Library, 1999.
4. Kwakkel G, Wagenaar RC, Koelman TW, Lankhorst GJ, Koetsier JC. Effects of intensity of rehabilitation after stroke: a research synthesis. Stroke 1997;28:1550-1556.
5. Kwakkel G, Wagenaar RC, Twisk JWR, Lankhorst GJ, Koetsier JC. Intensity of leg and arm training after primary middle-cerebralartery stroke: A randomized trial. Lancet 1999;354:191-196.
6. Goldstein LB. Restorative neurology: Advances in Pharmacotherapy for Recovery After Stroke. New York: Futura Publishing, 1998.
7. Goldstein LB. Pharmacologic effects on recovery of neurologic function. In: Lazar RB, ed. Principles of Neurologic Rehabilitation. New York: McGraw Hill, 1998:565-578.
8. Feeney DM. Rehabilitation pharmacology: noradrenergic enhancement of physical therapy. In: Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease. Blackwell Science, 1998:620-636.
9. Geldmacher DS. Enhancing recovery from ischemic stroke. Neurosurg Clin N Am 1997;2:245-251.
10. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982;217:855-857.
11. Feeney DM. Amphetamine restores locomotor function after motor cortex injury in the rat. Proc West Pharmacol Soc 1981;24:15-17.
12. Dunbar GL, Smith GA, Look SK, Whaler RJ. δ-amphetamine attenuates learning and motor deficits following cortical injury in rats. Soc Neurosci Abstr 1989;15:132 (Abstract).
13. Goldstein LB, Davis VA. The role of experience on amphetamine-facilitated recovery of beam-walking in the rat. Soc Neurosci Abstr 1989;15:69(Abstract).
14. Goldstein LB, Davis JN. postlesion practice and amphetamine-facilitated recovery of beam-walking in the rat. Restor Neurol Neurosci 1990;2:311-314.
15. Goldstein LB. Amphetamine-facilitated functional recovery after stroke. In: Ginsberg MD, Dietrich WD, eds. Cerebrovascular Diseases. New York: Raven Press, 1989:303-308.
16. Sutton RL, Feeney DM. α-noradrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation in the rat. Restor Neurol Neurosci 1992;4:1-11.
17. Irish SL, Davis GW, Barth TM. A specific behavioral role for norepinephrine in the recovery of locomotor placing following cortical lesions in the rat. Soc Neurosci Abstr 1995;21:170 (Abstract).
18. Goldstein LB. The influence of lesion size and location on amphetamine facilitated recovery of beam walking in rats. Behav Neurosci 1990;104:320-327.
19. Hovda DA, Fenney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res 1984;298:358-361.
20. Feeney DM. Amphetamine and apomorphine restore tactile placing after motor cortex injury in the cat. Psychopharmacology 1983;79:67-71.
21. Sutton RL, Hovda DA, Feeney DM. Amphetamine accelerates recovery of locomotor function following bilateral frontal cortex ablation in cats. Behav Neurosci 1989;103:837-841.
22. Salo AA, Feeney DM. Reduction of morbidity, mortality, and lesion size in a rat model of cerebral infarction with amphetamine. Soc Neurosci Abstr 1987;13:1268( Abstract).
23. Stroemer RP, Kent TA, Hulsebosch CE. Amphetamines permanently promote recovery following cortical infarction. Soc Neurosci Abstr 1994;20:186(Abstract).
24. Hurwitz BE, Dietrich WD, McCabe PM, et al. Amphetamine promotes recovery from sensory-motor integration deficit after thrombotic infarction of the primary somatosensory rat cortex. Stroke 1991;22:648-654.
25. Dietrich WD, Alonso O, Busto R, et al. Influence of amphetamine treatment on somatosensory function of the normal and infarcted rat brain. Stroke 1990;21:147-150.
26. Feeney DM, Hovda DA. Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation. Brain Res 1985;342:352-356.
27. Hovda DA, Feeney DM. Haloperidol blocks amphetamine-induced recovery of binocular depth perception after bilateral visual cortex ablation in cats. Proc West Pharmacol Soc 1985;28:209-211.
28. Hovda DA, Sutton RL, Feeney DM. Amphetamine-induced recovery of visual cliff performance after bilateral visual cortex ablation in cats: measurement of depth perception thresholds. Behav Neurosci 1989;103:574-584.
29. Cornwell P. Performance on the visual cliff by cats with marginal gyrus lesions. Physiol Psychol 1976;90:996-1010.
30. Boyeson MG, Feeney DM. Adverse effects of catecholaminergic agonists and antagonists on recovery of locomotor ability following unilateral cerebellar ablations. Restor Neurol Neurosci 1991;3:227-233.
31. Mintz M, Tomer R. Exposure to amphetamine after substantia nigra lesion interferes with the process of behavioral recovery. Pharmacol Biochem Behav 1986;25:1307-1311.
32. Goldstein LB. Pharmacology of recovery after stroke. Stroke 1990;21(suppl III):III-139-III-142.
33. Prasad MR, Ramaiah C, McIntosh TR, et al. Regional levels of lactate and norepinephrine after experimental brain injury. J Neurochem 1994;63:1086-1094.
34. Dunn-Meynell A, Pan S, Levin BE. Focal traumatic brain injury causes widespread reductions in rat brain norepinephrine turnover from 6 to 24 hr. Brain Res 1994;660 :88-95.
35. Robinson RG, Shoemaker WJ, Schlumpf M, Coyle JT. Effect of experimental cerebral infarction in rat brain on catecholamines and behavior. Nature 1975;255:332-334.
36. Robinson RG. Differential behavioral and biochemical effects of right and left hemispheric cerebral infarction in the rat. Science 1979;205:707-710.
37. Finklestein S, Campbell A, Baldessarini RJ, Moya K, Haber SN. Late changes in cerebral monoamine metabolism following focal ventrolateral cerebrocortical lesions. Brain Res 1985;344:205-210.
38. Boyeson MG, Feeney DM. Striatal dopamine after cortical injury. Exp Neurol 1985;89:479-483.
39. Meyer JS, Stoica E, Pascu I, Shimazu K, Hartmann A. Catecholamine concentrations in CSF and plasma of patients with cerbral infarction and hemorrhage. Brain 1973;96:277-288.
40. Brown RM, Carlson A, Ljungren BL, Seisjo BK, Snider SR. Effect of ischemia on monoamine metabolism in the brain. Acta Physiol Scand 1974;90:789-791.
41. Cohen HP, Woltz AG, Jacobson RL. Catecholamine content of cerebral tissue after occlusion or manipulation of middle cerebral artery in cats. J Neurosurg 1975;43:32-36.
42. Prasad MR, Tzigaret CM, Smith D, Soares H, McIntosh TK. Decreased alpha 1-adrenergic receptors after experimental brain injury. J Neurotrauma 1992;9:269-279.
43. Levin BE, Pan S, Dunn-Meynell A. Chronic alterations in rat brain alpha-adrenoreceptors following traumatic brain injury. Restor Neurol Neurosci 1994;7:5-12.
44. Robinson RG, Shoemaker WJ, Schlumpf M. Time course of changes in catecholamines following right hemisphere cerebral infarction in the rat. Brain Res 1980;181:202-208.
45. Boyeson MG, Feeney DM. Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. Pharm Biochem Behav 1990;35:497-501.
46. Feeney DM, Weisend MP, Kline AE. Noradrenergic pharmacotherapy, intracerebral infusion and adrenal transplantation promote functional recovery after cortical damage. J Neurotransplantation 1994;4:199-214.
47. Boyeson MG, Harmon RL, Jones JL. Comparative effects of fluoxetine, amitriptyline and serotonin on functional motor recovery after sensorimotor cortex injury. Am J Phys Med Rehabil 1994;73:76-83.
48. 2-Adrenergic receptor antagonist. Ann Neurol 1989;26:157 (Abstract).
49. Feeney DM, Sutton RL. Catecholamines and recovery of function after brain damage. In: Sabel BA, Stein DG, eds. Pharmacological Approaches to the Treatment of Brain and Spinal Cord Injury. New York: Plenum, 1988:121-142.
50. Hovda DA. Phentermine accelerates recovery of function after motor cortex injury in rats and cats. FASEB J 1983;42:1157.
51. Kline AE, Chen MJ, Tso-Olivas DY, Feeney DM. Methylphenidate treatment following ablation-induced hemiplegia in rat: Experience during drug action alters effects on recovery of function Pharm Biochem Behav 1994;48:773-779.
52. Chen MJ, Sutton RL, Feeney DM. Recovery of function following brain injury in rat and cat: Beneficial effects of phenylpropanolamine. Soc Neurosci Abstr 1986;12:881 (Abstract).
53. Boyeson MG, Harmon RL. Effects of trazadone and desipramine on motor recovery in brain-injured rats. Am J Phys Med Rehabil 1993;72:286-293.
54. Goldstein LB, Coviello A, Miller GD, Davis JN. Norepinephrine depletion impairs motor recovery following sensorimotor cortex injury in the rat. Restore Neurol Neurosci 1991;3:41-47.
55. Boyeson MG, Callister TR, Cavazos JE. Biochemical and behavioral effects of a sensorimotor cortex injury in rats pretreated with the noradrenergic neurotoxin DSP-4. Behav Neurosci 1992;106:964-973.
56. Goldstein LB, Davis JN. Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat. Brain Res 1990;508:305-309.
57. Stephens J, Goldberg G, Demopoulos JT. Clonidine reinstates deficits following recovery from sensorimotor cortex lesion in rats. Arch Phys Med Rehabil 1986;67:666-667 (Abstract).
58. Feeney DM, Westerberg VS. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can J Psychol 1990;44:233-252.
59. Hovda DA, Feeney DM, Salo AA, Boyeson MG. Phenoxy-benzamine but not haloperidol reinstates all motor and sensory deficits in cats fully recovered from sensorimotor cortex ablations. Soc Neurosci Abstr 1983;9:1002 (Abstract).
60. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol 1988;23:94-97.
61. Reding M, Solomon B, Borucki SJ. Effect of dextroamphetamine on motor recovery after stroke. Neurology 1995;45:A222(Abstract).
62. Borucki SJ, Langberg J, Reding M. The effect of dextroamphetamine on motor recovery after stroke. Neurology 1992;42:329 (Abstract).
63. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Stroke 1995;26:2254-2259.
64. Walker-Batson D. Pharmacotherapy in the treatment of aphasia. In: Goldstein LB, ed. Restorative Neurology: Advances in Pharmacotherapy for Recovery after Stroke. New York: Futura Publishing, 1998:257-270.
65. Walker-Batson D, Devous Sr MD, Curtis S, Unwin DH, Greenlee RG. Response to amphetamine to facilitate recovery from aphasia subsequent to stroke. Clin Aphasiol 1990;20:137-143.
66. Walker-Batson D, Unwin H, Curtis S. Use of amphetamine in the treatment of aphasia. Restor Neurol Neurosci 1992;4:47-50.
67. Small SL. Pharmacotherapy of aphasia. A critical review. Stroke 1994;25:1282-1289.
68. Feeney DM. From laboratory to clinic: Noradrenergic enhancement of physical therapy for stroke or trauma patients. In: Freund HJ, Sabel BA and Witte OW. Advances in Neurology. 1997. Philadelphia: Lippincott-Raven Publishers, 383-394.
69. Smith P, Unwin H, Curtis S, Walker-Batson D. Negligible effects of amphetamine administration in stroke rehabilitation. Neurology. 1999;52:80-81.(Abstract).
70. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: A double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047-1050.
71. Goldstein LB, Davis JN. Physician prescribing patterns following hospital admission for ischemic cerebrovascular disease. Neurology 1988;38:1806-1809.
72. Goldstein LB. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury. J Neurol Neurosurg Psychiatry 1995;58:753-755.
73. Goldstein LB. Influence of common drugs and related factors on stroke outcome. Curr Opin Neurol 1997;10:52-57.
74. Goldstein LB. Potential effects of common drugs on stroke recovery. Arch Neurol 1999;55:454-456.
75. Goldstein LB. The Sygen in acute stroke study investigators. Common drugs may influence motor recovery after stroke. Neurology 1995;45:865-871.
76. Goldstein LB, Matchar DB, Morgenlander JC, Davis JN. Influence of drugs on the recovery of sensorimotor function after stroke. J Neurol Rehab 1990;4:137-144.
77. Graham GD, Ahmed W, Davis LE, et al. Effects of commonly prescribed medications on stroke recovery: a TOAST study analysis. Stroke 1999;30:236(Abstract).
78. Goldstein LB, Davis JN. Restorative neurology. Drugs and recovery following stroke. Stroke 1990;25:19-24.
79. Feeney DM. Mechanisms of noradrenergic modulation of physical therapy: effects on functional recovery after cortical injury. In: Goldstein LB, ed. Restorative Neurology: Advances in Pharmacotherapy for Recovery after Stroke. New York: Futura, 1998:35-78.
80. Feeney DM, Baron JC. Diaschisis. Stroke 1986;17:817-830.
81. Von Monakow C. Diaschisis. In: Pribram KH, ed. Brain and Behavior, Mood, States and Mind. Baltimore, Maryland: Penguin Book, 1969:27-36.
82. Nguyen DK, Botez MI. Diaschisis and neurobehavior. Can J Neurol Sci 1998;25:5-12.
83. Feeney DM. Pharmacologic modulation of recovery after brain injury: a reconsideration of diaschisis. J Neurol Rehab 1991;5:113-128.
84. Sutton RL, Feeney DM. Noradrenergic pharmacotherapy and functional recovery after cortical injury. In: Illis LS, ed. Neurological Rehabilitation. England: Blackwell, 1994:469-480.
85. Boyeson MG, Krobert KA. Cerebellar norepinephrine infusions facilitate recovery after sensorimotor cortex injury. Brain Res Bull 1992;29:435-439.
86. Bowler JV, Costa DC, Jones BE. High resolution SPECT, small deep infarcts and diaschisis. J R Soc Med 1992;85:142-146.
87. Seil FJ. Recovery and repair issues after stroke from the scientific perspective. Curr Opin Neurol 1997;10:49-51.
88. Johansson BB. Brain plasticity and stroke rehabilitation: the Willis lecture. Stroke 2000;31:223-230.
89. Lee RG, van Donkelaar P. Mechanisms underlying functional recovery following stroke. Can J Neurol Sci 1995:22:257-263.
90. Chollet F, Weiller C. Imaging recovery of function following brain injury. Curr Opin Neurobiol 1994;4:226-230.
91. Cramer SC, Nelles G, Benson RR, et al. A functional MRI study of subjects recovered from hemiparetic stroke. Stroke 1997;28: 2518-2527.
92. Silvestrini M, Cupini LM, Placidi F, Diomedi M, Bernardi G. Bilateral hemispheric activation in the early recovery of motor function after stroke. Stroke 1998;29:1305-1310.
93. Cao Y, D'Olhaberriague L, Vikingstad EM, Levine SR, Welch KMA. Pilot study of functional MRI to assess cerebral activation of motor function after poststroke hemiparesis. Stroke 1998;29:112-122.
94. Chollet F, DiPiero V, Wise RJS, et al. The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. Ann Neurol 1991;29:63-71.
95. Nudo RJ, Wise BM, SiFuentes F, Milliken GW. Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct. Science 1996;272:1791-1794.
96. Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke 1998;29:2381-2395.
97. Nudo RJ, Milliken GW. Reorganization of movement representations in primary motor cortex following focal ischemic infarcts in adult squirrel monkeys. J Neurophysiol 1996:75:2144-2149.
98. Dobkin BH. Neurorehabilitation: greater plasticity through chemicals and practice. Neurology Network Commentary 1998;2:171-174.
99. Kozlowski DA, James DC, Schallert T. Use-dependent exaggeration of neuronal injury after unilateral sensorimotor cortex lesions. J Neurosci 1996;16:4776-4786.
100. Stroemer RP, Kent TA, Hulsebosch CE. Neocortical neural sprouting, synaptogensis, and behavioral recovery after neocortical infarction in rats. Stroke 1995;26:2135-2144.
101. Kawamata T, Ren J, Chan TCK, Charette M, Finklestein SP. Intracisternal osteogenic protein-1 enhances functional recovery following focal stroke. Neuroreport 1998;9:1441-1445.
102. Kawamata T, Alexis NE, Dietrich WD, Finklestein SP. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J Cereb Blood Flow Metab 1996;16:542-547.
103. Dietrich WD, Alonso O, Busto R, Ginsberg MD. The effect of amphetamine on functional brain activation in normal and postinfarcted rat. Stroke 1990;21:147-150.
104. Gold P, Delanoy R, Merrin J. Modulation of long-term potentiation by peripherally administered amphetamine and epinephrine. Brain Res 1984;305:103-107.
105. Classen J, Liepert J, Wise SP. Hallett M, Cohen LG. Rapid plasticity of human cortical movement representation induced by practice. J Neurophysiol 1998;79:1117-1123.
106. Cohen LG, Davis B. Pharmacological enhancement of plasticity in the human motor cortex. Neurology 1999;52:A15(Abstract).
107. Loubinoux I, Boulanlouar K, Ranjeva JP. et al. Cerebral fRMI activation modulated by a single dose of the monoamines neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. Neurology 1999;52:A15(Abstract).
108. Mattay VS, Bentian KF, Ostrem JL, et al. Dextroamphetamine enhances "Neural network-specific" physiological signals: a positron-emission tomography rCBF study. J Neurosci 1996;16: 4816-4822.
109. Uftring SJ, Chu D, McCandless C, et al. An fMRI study of the efffects of amphetamine on brain activity. Neuroimage 1999:( Abstract)